drugset / Trial / NCT00268996

Integrated Biomarker And Imaging Study - 2

NCT00268996

Phase 2 Completed 336 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.

Timeline

Start
2005-11-10
Primary completion
2007-08-28
Completion
2007-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Darapladib Small molecule 160 mg

Indications